Austin, TX 10/11/2007 9:02:44 PM
Speak with other shareholders about: (Nasdaq: GNBT), (OTCBB: SPKL), (OTCBB: MCET), and (OTCBB: ETLC) .
AUSTIN, TX: October 11, 2007 – Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the “Chat Live” button at the top.
----------------------------------------------------------
Chat real-time with other investors about this GNBT news release, by clicking this link: http://www.stockwire.com/GNBT
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=GNBT
Generex Biotechnology Corporation (Nasdaq: GNBT)
Oct. 9th, 2007-- Generex Biotechnology Corporation (Nasdaq: GNBT) announced today that Dr. Minzhen Xu, Vice President of Biology at Antigen Express, Inc., the Company's immunotherapy subsidiary, will make a presentation at a scientific symposium on the Company's strategy for converting cancer cells into potent tumor vaccine cells Dr. Xu will present "Inhibition of MHC class II-associated Invariant Chain Generates Potent Tumor Cell Vaccine" at the 12th World Congress on Advances in Oncology to be held at the Creta Maris Hotel, Hersonissos, Crete, Greece, to be held from Oct. 11 through the 13th. The conference will focus on a variety of aspects of tumor biology and therapeutics. Dr. Xu will co-Chair and present in the Experimental Therapeutics/Vaccines section on Oct. 13th.
The talk by Dr. Xu will present pre-clinical studies that Antigen Express has performed in preparation for clinical trials in China. Robust anti-tumor immunity has been demonstrated in a variety of mouse tumor models as well as safety using the RNAi approached developed at Antigen Express. The trials in China will be performed in collaboration with Dr. Daopei Lu and the Beijing Daopei Hospital in Beijing, China. Dr. Lu is a world-renowned hematologist-oncologist who has conducted many clinical trials and has authored over 200 articles in peer-review journals.
The strategy being developed by Antigen Express is to force tumor cells to express tumor associated antigens in a way that that makes them more visible to the immune system. This is done by suppressing expression of the MHC class II-associated invariant chain in tumor cells using RNAi. MHC class II molecules are naturally expressed in many cells of the body including some types of cancer cells. The invariant chain prevents class II molecules from associating with antigenic peptides in the cytoplasm of cells (where tumor associated antigens are found) and presenting them for recognition by T helper cells. Antigen-specific stimulation of T helper cells is pivotal in allowing the immune system to recognize novel pathogenic agents. While a number of groups have demonstrated the efficacy of this strategy in pre-clinical models, Antigen Express has developed proprietary methods using RNAi that make this approach feasible in the clinic.
Antigen Express is focused on developing active immunotherapy products for serious diseases and unmet medical needs. Currently the company has an immunotherapeutic peptide in Phase II clinical trials for breast cancer and in Phase I trials for the potentially pandemic H5N1 avian influenza.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
----------------------------------------------------------
Chat real-time with other investors about this SPKL news release, by clicking this link: http://www.stockwire.com/SPKL
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=SPKL
Spicy Pickle (OTCBB: SPKL)
Oct. 9th, 2007-- Spicy Pickle fast casual restaurants announced two new stores have opened in the past week, bringing the current total to 28 stores open.
Both new sites are in Colorado, and represent the continued penetration of the Denver Rocky Mountain Front Region where Spicy Pickle is a branded and well-recognized name.
The first store opened in the North Boulder area. It is located at 2520 Broadway, Boulder, CO 80304. This is the second store for the Boulder-based franchisee, the first being one of the highest revenue stores in the entire chain.
The second store is in Johnstown, CO. Johnstown is located on the highly populated I-25 corridor north of Denver, on route to Fort Collins. The store is located at 4791 Thompson Parkway, Johnstown, CO 80534.
Marc Geman, CEO of Spicy Pickle Franchising, Inc., commented: "As our brand expands in the Colorado region, more consumers will recognize our name. This should fuel increasing same store sales. We plan to follow this model in other major metropolitan areas around the country where we currently have a foothold."
By the end of 2007, Spicy Pickle anticipates opening approximately 12 more units, bringing its network to 40 restaurants in 13 states. Nearly 50 additional franchise development agreements have also been signed.
In addition to its franchise activity, Spicy Pickle currently has a breakfast menu in test, potentially opening a new daypart for the chain. The company is also in the process of building a major commissary in Denver to cost-effectively supply its local restaurants with panini, sandwich breads and sweet treats, baked daily according to Spicy Pickle's high standards. All other units nationwide will continue to bake their panini and sandwich breads in-house. The Denver commissary is expected to open by the end of the year.
----------------------------------------------------------
Chat real-time with other investors about this MCET news release, by clicking this link: http://www.stockwire.com/MCET
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=MCET
MultiCell Technologies, Inc. (OTCBB: MCET)
Oct. 10th, 2007-- MultiCell Technologies, Inc. (OTCBB: MCET), entered into a worldwide exclusive license and technology purchase agreement with Corning Incorporated of Corning, NY concerning the Company's Fa2N-4 immortalized adult human liver cell lines.
Corning paid MultiCell a license fee, and has agreed to purchase certain inventory and equipment related to MultiCell's Fa2N-4 cell line business, hire certain MultiCell scientific personnel, and pay for access to MultiCell's laboratories during transfer of the Fa2N-4 cell lines to Corning.
MultiCell will retain and continue to support all of its existing licensees, including Pfizer, Bristol-Myers Squibb, and Eisai. MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol(R) liver assist device, to produce therapeutic proteins using the Company's BioFactories(TM) technology, to identify drug targets and for other applications related to the Company's internal drug development programs.
"We are pleased to partner with Corning in the drug discovery assay tools, ADME/Tox and biomarker segments. MultiCell's focus is on using our therapeutic antibody and Toll-like receptor (TLR) technologies to develop new drug candidates, and to advance our lead drug candidate, MCT-125, for the treatment of primary MS-related fatigue," said Jerry Newmin, Chairman of the Board of MultiCell Technologies.
The foregoing events are further described in a Current Report on Form 8-K that Multicell Technologies filed on October 10, 2007 with the Securities and Exchange Commission.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a biopharmaceutical company committed to the development of new drug candidates and whose current drug candidates include:
-- MCT-125 for the treatment of primary fatigue in MS patients.
-- MCT-175 for the treatment of relapsing-remitting MS.
-- MCT-465 for the treatment of TLR3 positive breast cancers.
-- MCT-475 for the treatment of TLR3 positive cervical cancers.
----------------------------------------------------------
Chat real-time with other investors about this ETLC news release, by clicking this link: http://www.stockwire.com/ETLC
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=ETLC
Etelcharge.com (OTCBB: ETLC)
Oct. 9th, 2007-- Etelcharge.com (OTCBB: ETLC) (www.etelcharge.com), the new online way to pay(TM), announced today it has entered into a merchant agreement with CRS Corporation of Pasadena, CA. "This represents a significant revenue growth opportunity for us as those qualifying CRS customers can pay for their CRS services using their Etelcharge memberships," said Rob Howe, Etelcharge Chairman and CEO. "Likewise, Etelcharge members will be able to benefit from the services provided by CRS in seeking to extend their ability to obtain home and auto financing," Howe added. CRS data is accepted by such lenders as Wells Fargo Home Mortgage, Chase Home Finance, GMAC RFC, CitiMortgage, Wachovia Corp., US Bancorp and other FHA lenders.
"For over 10 years, CRS has designed innovative solutions to help consumers who are concerned about identity theft and who are outside the traditional banking world, and we're excited to offer our thousands of consumers access to the Etelcharge program," said Ray Smith, President of CRS. "We see Etelcharge as a way to open new payment methods for our non-traditional customer base, beginning with utilizing the Etelcharge payment system as a way for them to pay for our services." Etelcharge and CRS will also work together to provide innovative programs which leverage Etelcharge's unique payments technology.
Howe went on to say, "CRS provides an alternative way of establishing a reliable credit profile -- something many really need. For example, Reportmybills.com is a CRS product that measures lease payments, utilities payments, insurance payments and others -- one of which could be their payment reliability record when they pay with Etelcharge. By teaming up with CRS, Etelcharge provides our members with a credit reporting option that's in alignment with the way they live, work and pay their bills."
The two companies agreed that Etelcharge and CRS will work together with CRS's contacts outside the US to implement the Etelcharge payment system technology internationally.
About Etelcharge.com
Etelcharge.com (OTCBB: ETLC), the first Web 2.0 online payment system, provides online shoppers the ability to charge approved transactions to their telephone bill. While addressing the concerns online shoppers have about identity fraud and identity theft, the Etelcharge payment option is also a perfect match for the millions of individuals without a credit card, or even a bank account.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
